Duyuru • Mar 30

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio, Inc. announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platform (under exclusive worldwide license with Younet). The launch follows the Company's March 11 announcement that its first AI agent would ship within 14 days, a commitment Kala has met on schedule, demonstrating the Company's ability to execute on commitments and its readiness to deliver commercial-grade AI solutions at enterprise scale. The Bionic Intelligence Research Agent is a fully autonomous AI research specialist built for the biotechnology and pharmaceutical sectors. Powered by Researgent 2.0, a 70-billion-parameter large language model trained on vast datasets in the biotech, healthcare, and scientific research sectors, BIRA delivers next-generation performance within secure enterprise infrastructure. BIRA operates solely within client-controlled, VPN-secured environments, guaranteeing full data sovereignty with no external access to proprietary research data; enterprise-grade security that complies with pharmaceutical R&D standards; complete audit trails for regulatory documentation; and real-time performance with minimal cloud latency. Autonomous Research Execution: The platform delivers multi-step query decomposition and cross-source synthesis from scientific literature, clinical trial databases, patent repositories, and pharma intelligence feeds via advanced automation. Comprehensive Database Connectivity: Pre-built connectors provide integration with scientific literature, clinical and regulatory databases, global IP resources, market intelligence, and business data through a single secure interface. Private Infrastructure Deployment: VPN-only access ensures all queries, results, and derived intelligence remain within organizational boundaries, maintaining complete security throughout the research workflow. Quality Assurance & Confidence Scoring: Automated source verification, reliability scoring of quantitative evidence, and explicit flagging of knowledge gaps ensure enterprise-grade performance for research teams. Research-Ready Visualization: Interactive, customisable graphical presentations designed for R&D decision-making enable real-time analysis and reporting. BIRA's architecture integrates smoothly with Younet's Researgency platform infrastructure, designed to scale with the complexity of client organisations, leverage existing enterprise infrastructure investments, support a platform-as-a-service model for recurring revenue, and enable swift deployment across multiple business units. This scalable approach ensures that organizations of any size can benefit from the platform's AI solutions without sacrificing security or performance. Building on BIRA's foundation, Younet's engineering team in collaboration with Kala is actively developing four additional capabilities for near-term release, each representing significant innovation in agentic AI for the life sciences sector: Daily Compressed Publications Review: An automated, scheduling-driven research digest that delivers AI-compressed summaries of publications across user-defined therapeutic verticals, such as oncology, neurology, and immunology. This automation solution includes text-to-speech for hands-free consumption and uses machine-learning-based priority filtering to highlight the most impactful findings in real time. Trigger-Defined Real-Time Alerts: A versatile event-monitoring system that supports keyword triggers, alerts for starting clinical trials, notifications for regulatory decisions, and complex logic conditions from multiple sources. Alerts are sent via email, dashboard, mobile, or voice, with ML-driven false-positive reduction to ensure enterprise-grade reliability and performance. Real-Time IP Filings Monitoring: Continuous monitoring of global patent filings with competitor tracking, technology area analysis, citation review, white-space detection, and freedom-to-operate risk alerts. This platform capability provides biotech and pharma organizations a real-time advantage in IP strategy through seamless integration with existing research workflows. Prospective Dormant IP Identification: An intelligence module that systematically detects lapsed or abandoned patents with revival potential, cross-checks with client internal research priorities, and produces prioritized strategic recommendations with risk-benefit analysis. This innovation unlocks hidden value in the global IP landscape while maintaining complete security of proprietary analysis. The launch of BIRA marks a significant turning point for Kala Bio. The Company has transitioned from platform readiness and strategic announcements to live commercial deployment precisely within the timeframe it communicated to the market. With BIRA now commercially live, the Researgency.ai platform has moved from a strategic ambition to an active revenue-generating opportunity. Key strategic milestones achieved include transitioning from platform readiness to live commercial deployment, deploying operational enterprise-grade AI infrastructure, implementing a scalable platform architecture, creating an active, revenue-generating opportunity, and establishing a full platform commercialization roadmap. The Bionic Intelligence Research Agent integrates seamlessly with Younet's Researgency platform infrastructure and is designed to complement, not replace, existing multi-LLM research workflows. Its design scales with organisational complexity, leverages existing enterprise infrastructure investments, and supports a platform-as-a-service model aimed at generating recurring revenue. With thousands of biotech and pharma companies worldwide facing research bottlenecks, compliance challenges, and competitive intelligence issues, BIRA is positioned to tap into a significant market opportunity. The target market includes the global biotechnology and pharmaceutical sectors. The platform's main differentiation is its on-premises secure deployment model compared to public cloud AI options. Its core value proposition focuses on proprietary data control combined with enterprise-scale AI performance, while the revenue model is based on platform-as-a-service with scalable recurring income potential. Kala is now an operational AI infrastructure partner to the global biotech industry, delivering solutions that combine next-generation agentic capabilities with uncompromising security, though no assurance can be given that it will capture any specific portion of that market, or that its efforts in that market will generate substantial recurring revenue or be profitable.

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	6.7yrs
Yönetim Kurulu ortalama görev süresi	less than a year

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mary Reumuth	Treasurer & Secretary	12.5yrs	US$1.38m	Veri yok
Avi Minkowitz	CEO, CFO & Director	less than a year	Veri yok	Veri yok
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jill Steier	Executive Director of Investor Relations & Corporate Communications	5.1yrs	Veri yok	Veri yok
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	9.1yrs	Veri yok	Veri yok
Francis Mah	Chief Medical Advisor	3.4yrs	Veri yok	Veri yok
Josiah Craver	Senior VP & Corporate Controller	4.3yrs	Veri yok	Veri yok
Carl Rennie	Executive Director of Account Management	8.3yrs	Veri yok	Veri yok
Patrick Bedell	Executive Director of Trade & Alternate Channels	8.3yrs	Veri yok	Veri yok

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Avi Minkowitz	CEO, CFO & Director	less than a year	Veri yok	Veri yok
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Silverstein	Board Observer	10.3yrs	Veri yok	Veri yok
Peter Hutt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ronald Krall	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bennett Shapiro	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Colin Gardner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brendan Purdy	Independent Director	less than a year	Veri yok	Veri yok
Yonatan Colman	Independent Director	less than a year	Veri yok	Veri yok
Chaim Berger	Independent Director	less than a year	Veri yok	Veri yok
Hillel Posen	Independent Director	less than a year	Veri yok	Veri yok

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/05 13:38
Gün Sonu Hisse Fiyatı	2026/05/08 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Biren Amin	Jefferies LLC
Christopher Neyor	J.P. Morgan

KALA BIO Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

KALA BIO, Inc. announced delayed 10-Q filing

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

KALA BIO, Inc. announced delayed annual 10-K filing

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio Announces Launch Of First Commercial AI Product

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

Kala Bio, Inc. Receives Notice of Nasdaq Minimum Bid Price Non-Compliance

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $9.99909 million.

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO, Inc. announced delayed 10-Q filing

KALA BIO, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

KALA BIO, Inc. announced that it expects to receive $0.375 million in funding

KALA BIO, Inc. Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New minor risk - Share price stability

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Third quarter 2022 earnings released: EPS: US$19.40 (vs US$21.62 loss in 3Q 2021)

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Insufficient new directors

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

Revenue misses expectations

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları